Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.

Clin Exp Gastroenterol · 2024 · PMC11472755 · PMID 39403342

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The primary endpoint, clinical response defined by fistula reduction, showed a trend favoring the ciprofloxacin group (73% vs 39% in the placebo group), although not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.